Genmab A/S
DOSING REGIMENS FOR ANTI-TF-ANTIBODY DRUG-CONJUGATES

Last updated:

Abstract:

Anti-TF antibody drug conjugate and pharmaceutical compositions comprising the antibody drug-conjugate for use in the treatment of a solid cancer comprising administering to a subject a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an anti-TF antibody drug conjugate once a week for three consecutive weeks followed by a one week resting period without any administration of anti-TF ADC so that each cycle time is 28 days including the resting period.

Status:
Application
Type:

Utility

Filling date:

10 Dec 2021

Issue date:

25 Aug 2022